RZL-12 is under clinical development by Raziel Therapeutics and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RZL-12’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RZL-12 is under development for the treatment of obesity, submental fat reduction, lipedema involving substantial fat above the knee and nodular Dercum's disease. The drug candidate is a new chemical entity administered through subcutaneous route.
Raziel Therapeutics overview
Raziel Therapeutics, a clinical-stage pharmaceutical company that developing RZL-012, an injectable treatment for aesthetics and a variety of fat disorders. The company is headquartered in Israel.
For a complete picture of RZL-12’s drug-specific PTSR and LoA scores, buy the report here.